YDES

YD Bio Ltd

2.45

Jul 17 • 03:59PM ET -0.01 (-0.41%)

2.45

Aftermarket • 04:15PM ET 0.00 (0.00%)

Healthcare Biotechnology Taiwan Micro NASD

Peers: INCY BMRN KRYS KYMR NUVL RYTM AXSM MDGL VKTX NBIX

| Held by: ONEQ

Scroll to Statements

Index	-
Market Cap	173.43M
Enterprise Value	173.42M
Income	-2.97M
Sales	0.00M
Book/sh	-4.77
Cash/sh	0.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	15
IPO	Dec 23, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	17343.21
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.02
Current Ratio	0.02
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-0.99
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- 6.41%
Sales past 3/5Y	- -
EPS Y/Y TTM	14.61%
Sales Y/Y TTM	-
EPS Q/Q	-116.03%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	80.12%
Insider Trans	0.00%
Inst Own	0.23%
Inst Trans	-
ROA	-43.61%
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	6.08%
SMA50	-26.60%
SMA200	-72.41%
Trades

Shs Outstand	70.79M
Shs Float	14.07M
Short Float	0.08%
Short Ratio	0.09
Short Interest	0.01M
52W High	25.00 -90.20%
52W Low	1.70 44.12%
Volatility	13.09% 21.23%
ATR (14)	0.41
RSI (14)	46.19
Beta	-0.54
Rel Volume	0.15
Avg Volume	128.78K
Volume	19,920

Perf Week	9.87%
Perf Month	-7.89%
Perf Quarter	-53.77%
Perf Half Y	-79.24%
Perf YTD	-79.90%
Perf Year	-79.88%
Perf 3Y	-77.79%
Perf 5Y	-75.55%
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	2.46
Price	2.45
Change	-0.41%

Jul-02-26 08:00AM	YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations (GlobeNewswire) -17.75%
Apr-30-26 06:00PM	YD Bio Limited Reports Full Year 2025 Financial Results (GlobeNewswire) -5.88%
Mar-31-26 08:00AM	YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States (GlobeNewswire)
Mar-17-26 08:00AM	YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem (GlobeNewswire) -8.55%
Feb-25-26 08:00AM	YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform (GlobeNewswire)
08:30AM	Loading…
Jan-29-26 08:30AM	YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy (GlobeNewswire) -9.89%
Jan-06-26 09:00AM	YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation-Driven AI Platforms for Cancer Diagnostics and Drug Development (GlobeNewswire) -8.04%
Jan-05-26 09:00AM	YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap (GlobeNewswire) +5.67%
Dec-16-25 09:00AM	YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center (GlobeNewswire)
Dec-09-25 09:00AM	YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN (GlobeNewswire) -18.42%
Dec-02-25 09:00AM	YD Bio Limited Expands OkaiDx Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection (GlobeNewswire)
Nov-24-25 09:00AM	YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics (GlobeNewswire)
Nov-05-25 08:30AM	YD Bio and EG BioMed Expand U.S. Access to OkaiDx, a cfDNA-Methylation Blood Test for Post-Treatment Breast Cancer Monitoring (GlobeNewswire)
Oct-20-25 10:20AM	YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES (GlobeNewswire)
Oct-10-25 08:37AM	YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities (GlobeNewswire) -6.95%
07:30AM	Loading…
Aug-29-25 07:30AM	YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market (PR Newswire) +135.85%

YD Bio Ltd. is a biotechnology company building an integrated healthcare platform across regulated diagnostics, clinical services, and commercial healthcare markets. It operates DNA methylation-based oncology testing programs under an LDT-first strategy and provides compliant life science distribution and clinical trial supply chain services to pharmaceutical and biotechnology partners. The company's offerings include cancer detection products, regenerative ophthalmology solutions, and exosome-based technologies. YD Bio was founded on February 6, 2024 and is headquartered in Taipei, Taiwan.

CEO & ChairmanDr. Ethan Shen Ph.D.

F.C.A.Mr. Edmund Hen CPA

Chief Medical Officer & DirectorDr. Benjamin Zhang M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

YDES

YD Bio Ltd

Upgrade your Finviz experience